British Business Bank invests £25m in Alchemab Therapeutics, its largest direct investment in a life sciences company
British Business Bank invests £25m in Alchemab Therapeutics, its largest direct investment in a life sciences company Simon Cottam Thu, 07/09/2026 - 00:00 Content Typology Press release British…
Read the full articleYou might also wanna read
Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet
Alchemab Therapeutics, a London-based clinical-stage BioTech startup, has extended its Series A financing with €29.3 million (£25 million/$3
Alchemab Therapeutics extends Series A with £25m investment
Alchemab Therapeutics has extended its Series A financing with £25m from the British Business Bank, marking the Bank’s largest investment in
Alchemab Therapeutics Announces Biggest Ever Life Sciences Investment from British Business Bank to Advance its AI-Enabled Clinical Pipeline of Next-Generation Human-Derived Antibodies
Alchemab Therapeutics, pioneering the next generation of antibody therapeutics for hard-to-treat diseases, led by Jane Osbourn, OBE, FMedSci
BioNTech’s investment provides a template for UK growth, say ABPI
The innovative biopharmaceutical company BioNTech has announced a major investment of up to £1bn over 10 years in the UK, potentially creati
ABPI celebrates a month of major investment commitments into UK life sciences
Following two new major investments in UK life sciences in April - £300 million by AstraZeneca, and £150 million by Boehringer Ingelheim - t
Proteina Invests 3.4 Billion Won in ABX to Expand AI-Based Antibody Design
Proteina will invest 3.4 billion won in ABX Biosciences and become its largest shareholder to expand AI-based de novo antibody drug design a
Comments
Sign in to join the conversation.
No comments yet. Be the first.